Patent office india published patent information - august 12th, 2011

¯Öê™ëü™ü úÖµÖÖÔ»ÖµÖ
úÖ
¿ÖÖÃÖúßµÖ •Ö−ÖÔ»Ö

OFFICIAL JOURNAL
OF
THE PATENT OFFICE

×−ÖÖÔ´Ö−Ö ÃÖÓ. 32/2011 ¿ÖãÎú¾ÖÖ¸ü ×¤ü−ÖÖÓú: 12/08/2011
ISSUE NO. 32/2011 FRIDAY DATE: 12/08/2011

¯Öê™ëü™ü úÖµÖÖÔ»ÖµÖ úÖ ‹ú ¯ÖÏúÖ¿Ö−Ö
PUBLICATION OF THE PATENT OFFICE

The Patent Office Journal 12/08/2011 13337

INTRODUCTION

In view of the recent amendment made in the Patents Act, 1970 by the Patents (Amendment) Act, 2005
effective from 01st January 2005, the Official Journal of The Patent Office is required to be published
under the Statute. This Journal is being published on weekly basis on every Friday covering the various
proceedings on Patents as required according to the provision of Section 145 of the Patents Act 1970. All the
enquiries on this Official Journal and other information as required by the public should be addressed to the
Controller General of Patents, Designs & Trade Marks. Suggestions and comments are requested from all
quarters so that the content can be enriched.

(P H Kurian)
CONTROLLER GENERAL OF PATENTS, DESIGNS & TRADE MARKS

12 TH AUGST, 2011


CONTENTS

SUBJECT PAGE NUMBER
JURISDICTION
: 13340 – 13341

SPECIAL NOTICE : 13342 – 13343

PUBLICATION U/S. 87(1) : 13344 – 13363
EARLY PUBLICATION (DELHI) : 13364 – 13365
EARLY PUBLICATION (MUMBAI) : 13366 – 13369
EARLY PUBLICATION (CHENNAI) : 13370 – 13377
EARLY PUBLICATION (KOLKATA) 13378 – 13379
PUBLICATION AFTER 18 MONTHS (DELHI) : 13380 – 13392
PUBLICATION AFTER 18 MONTHS (MUMBAI) : 13393 – 13407
PUBLICATION AFTER 18 MONTHS (CHENNAI) : 13408 – 13686
PUBLICATION AFTER 18 MONTHS ( KOLKATA )
: 13687 – 13728
AMENDMENT UNDER SEC.57. (KOLKATA) : 13729
PUBLICATION UNDER SECTION 43(2) IN
RESPECT OF THE GRANT (DELHI) : 13730

RESPECT OF THE GRANT (MUMBAI) : 13731 – 13732

RESPECT OF THE GRANT (CHENNAI) : 13733

RESPECT OF THE GRANT (KOLKATA) : 13734

INTRODUCTION TO DESIGN PUBLICATION : 13735

COPYRIGHT PUBLICATION : 13736
REGISTRATION OF DESIGNS : 13737 - 13786


THE PATENT OFFICE
KOLKATA, 12/08/2011
Address of the Patent Offices/Jurisdictions
The following are addresses of all the Patent Offices located at different places having their
Territorial Jurisdiction on a Zonal basis as shown below:-
1 Office of the Controller General of Patents, 4 The Patent Office,
Designs & Trade Marks, Government of India,
Boudhik Sampada Bhavan, Intellectual Property Rights Building,
Near Antop Hill Post Office,S.M.Road,Antop Hill, G.S.T. Road, Guindy,
Mumbai – 400 037 Chennai – 600 032.

Phone: (91)(22) 24123311, Phone: (91)(44) 2250 2081-84
Fax : (91)(22) 24123322 Fax : (91)(44) 2250 2066
E-mail: cgpdtm@nic.in E-mail: chennai-patent@nic.in
The States of Andhra Pradesh,
Karnataka, Kerala, Tamil Nadu and the
Union Territories of Puducherry and
Lakshadweep.

2 The Patent Office,
Government of India, 5 The Patent Office (Head Office),
Boudhik Sampada Bhavan, Government of India,
Near Antop Hill Post Office,S.M.Road,Antop Hill, Boudhik Sampada Bhavan,
Mumbai – 400 037 CP-2, Sector –V, Salt Lake City,
Phone: (91)(22) 24137701 Kolkata- 700 091
Fax: (91)(22) 24130387
E-mail: mumbai-patent@nic.in Phone: (91)(33) 2367 1943/44/45/46/87
The States of Gujarat, Maharashtra, Madhya Fax: (91)(33) 2367 1988
Pradesh, Goa and Chhattisgarh and the Union E-Mail: kolkata-patent@nic.in
Territories of Daman and Diu & Dadra and
Nagar Haveli
Rest of India
3 The Patent Office,
Government of India,
Boudhik Sampada Bhavan,
Plot No. 32., Sector-14, Dwarka,
New Delhi – 110075
Phone: (91)(11) 2808 1921 – 25
Fax: (91)(11) 2808 1920 & 2808 1940
E.mail: delhi-patent@nic.in
The States of Haryana, Himachal Pradesh,
Jammu and Kashmir, Punjab, Rajasthan, Uttar
Pradesh, Uttaranchal, Delhi and the Union
Territory of Chandigarh.
Website: www.ipindia.nic.in
www.patentoffice.nic.in
All applications, notices, statements or other documents or any fees required by the Patents Act, 1970
and The Patents (Amendment) Act, 2005 or by the Patents (Amendment) Rules, 2006 will be received
only at the appropriate offices of the Patent Office.
Fees: The Fees may either be paid in cash or may be sent by Bank Draft or Cheques payable to the
Controller of Patents drawn on a scheduled Bank at the place where the appropriate office is situated.


¯Öê™ëü™ü úÖµÖÖÔ»ÖµÖ
úÖê»ÖúÖŸÖÖ, ×¤ü−ÖÖÓ 12/08/2011
úÖµÖÖÔ»ÖµÖÖë êú Öê¡ÖÖ×¬ÖúÖ¸ü êú ¯ÖŸÖê
×¾Ö×³Ö®Ö •ÖÖÆüÖë ¯Ö¸ü ÛÃ£ÖŸÖ ¯Öê™êü−™ü úÖµÖÖÔ»ÖµÖ êú ¯ÖŸÖê †ÖÓ“Ö×»Öú †Ö¬ÖÖ¸ü ¯Ö¸ü ¤üÙ¿ÖŸÖ ˆ−Öúê ¯ÖÏÖ¤êü×¿Öú †×¬ÖúÖ¸ü Öê¡Ö êú ÃÖÖ£Ö
−Öß“Öê ×¤ü‹ Ö‹ Æïü :-
1 úÖµÖÖÔ»ÖµÖ: ´ÖÆüÖ×−ÖµÖÓ¡Öú, ‹úÃ¾Ö, †×³Öú»¯Ö 4 ¯Öê™ëü™ü úÖµÖÖÔ»ÖµÖ “Öê®Ö‡Ô,
ŸÖ£ÖÖ ¾µÖÖ¯ÖÖ¸ü ×“ÖÅ−Ö, ‡Ó™êü»ÖêŒ“Öã†»Ö ¯ÖÏÖê¯Ö™üá ¸üÖ‡™ËüÃÖ ×²ÖÜ»›üÖ
‹−Ö™üÖò¯Ö ×Æü»Ö ›üüÖú‘Ö¸ êú ÃÖ´Öß¯Öü, ‡Ó›üÛÃ™ÒüµÖ»Ö ‡Ã™êü™ü
‹ÃÖ. ‹´Ö. ¸üÖê›ü, ‹ÃÖ†Ö‡Ô›üßÃÖß†Öê †Ö¸ü‹´Ö›üß ÖÖê›üÖˆ−Ö ‹×¸üµÖÖ
‹−Ö™üÖò¯Ö ×Æü»Ö, ´Öã´²Ö‡Ô -400 037, ³ÖÖ¸üŸÖ. ‹›ü•ÖÃÖê−™ü ™ãü ‡ÔÖ»Ö °»ÖÖÃú
±úÖê−Ö: (91)(22) 24123311 •Öß.‹ÃÖ.™üß. ¸üÖê›ü, ÖÖµÖ−›üß,
±îúŒÃÖ: (91)(22) 24123322 “Öê®Ö‡Ô - 600 032.
‡Ô.´Öê»Ö: cgpdtm@nic.in ±úÖê−Ö: (91)(44) 2250 2081-84
±îúŒÃÖ: (91)(44) 2250-2066
‡Ô.´Öê»Ö: chennai-patent@nic.in
†Ö−¬ÖÐ ¯ÖÏ¤êü¿Ö, ú−ÖÖÔ™üú, êú¸ü»Ö, ŸÖ×´Ö»Ö−ÖÖ›ãü ŸÖ£ÖÖ
¯Öã›ãü“Öê¸üß ¸üÖ•µÖ Öê¡Ö ‹¾ÖÓ ÃÖÓ‘Ö ¿ÖÖ×ÃÖŸÖ Öê¡Ö, »ÖÖ«üß¯Ö
2 ¯Öê™ëü™ü úÖµÖÖÔ»ÖµÖ, ³ÖÖ¸üŸÖ ÃÖ¸üúÖ¸
²ÖÖî×¨üú ÃÖÓ¯Ö¤üÖ ³Ö¾Ö−Ö, 5 ¯Öê™ëü™ü úÖµÖÖÔ»ÖµÖ úÖê»ÖúÖŸÖÖ (¯ÖÏ¬ÖÖ−Ö úÖµÖÖÔ»ÖµÖ),
‹−Ö™üÖò¯Ö ×Æü»Ö ›üüÖú‘Ö¸ êú ÃÖ´Öß¯Öü, ²ÖÖî×¨üú ÃÖÓ¯Ö¤üÖ ³Ö¾Ö−Ö,
‹ÃÖ. ‹´Ö. ¸üÖê›ü, ÃÖß¯Öß-2, ÃÖêŒ™ü¸ü-V, ÃÖÖ»™ü »Öêú ×ÃÖ™üß,
‹−Ö™üÖò¯Ö ×Æü»Ö, ´Öã´²Ö‡Ô - 400 037, úÖê»ÖúÖŸÖÖ- 700 091, ³ÖÖ¸üŸÖ.
±úÖê−Ö: (91)(22) 2413 7701, ±úÖê−Ö: (91)(33) 2367 1943/44/45/46/87
±îúŒÃÖ: (91)(22) 2413 0387 ±îúŒÃÖ/Fax: (91)(33) 2367 1988
‡Ô.´Öê»Ö: mumbai-patent@nic.in ‡Ô.´Öê»Ö: kolkata-patent@nic.in
Öã•Ö¸üÖŸÖ, ´ÖÆüÖ¸üÖÂ™Òü, ´Ö¬µÖ ¯ÖÏ¤êü¿Ö, ÖÖê†Ö ŸÖ£ÖÖ ”û¢ÖßÃÖÖœÍü
¸üÖ•µÖ Öê¡Ö ‹¾ÖÓ ÃÖÓ‘Ö ¿ÖÖ×ÃÖŸÖ Öê¡Ö, ¤ü´Ö−Ö ŸÖ£ÖÖ ¤üß¾Ö, ¤üÖ¤ü¸ü ³ÖÖ¸üŸÖ úÖ †¾Ö¿ÖêÂÖ Öê¡Ö
†Öî¸ü −ÖÖ¸ü Æü¾Öê»Öß.

3 ¯Öê™ëü™ü úÖµÖÖÔ»ÖµÖ ×¤ü»»Öß,
²ÖÖî×¨üú ÃÖÓ¯Ö¤üÖ ³Ö¾Ö−Ö,
¯»ÖÖò™ü ÃÖÓ. 32, ÃÖêŒ™ü¸ü - 14,
«üÖ¸üúÖ, −Ö‡Ô ×¤ü»»Öß - 110 075.
±úÖê−Ö: (91)(11) 2808 1921-25
±îúŒÃÖ: (91)(11) 2808 1920, 2808 1940
‡Ô.´Öê»Ö: delhi-patent@nic.in
Æü×¸üµÖÖÖÖ, ×Æü´ÖÖ“Ö»Ö ¯ÖÏ¤êü¿Ö, •Ö´´Öæ ŸÖ£ÖÖ ú¿´Öß¸ü,
¯ÖÓ•ÖÖ²Ö, ¸üÖ•ÖÃ£ÖÖ−Ö, ˆ¢Ö¸ü ¯ÖÏ¤êü¿Ö, ×¤ü»»Öß ŸÖ£ÖÖ
ˆ¢Ö¸üÖÓ“Ö»Ö ¸üÖ•µÖ Öê¡ÖÖë, ‹¾ÖÓ ÃÖÓ‘Ö ¿ÖÖ×ÃÖŸÖ Öê¡Ö “ÖÓ›üßÖœÍü
¾Öê²ÖÃÖÖ‡™ü: http://www.ipindia.nic.in
www.patentoffice.nic.in
¯Öê™ëü™ü †×¬Ö×−ÖµÖ´Ö, 1970 ŸÖ£ÖÖ ¯Öê™ëü™ü (ÃÖÓ¿ÖÖê¬Ö−Ö) †×¬Ö×−ÖµÖ´Ö, 2005 †£Ö¾ÖÖ ¯Öê™ëü™ü (ÃÖÓ¿ÖÖê¬Ö−Ö) ×−ÖµÖ´Ö, 2006 «üÖ¸üÖ ¾ÖÖÓ×”ûŸÖ ÃÖ³Öß †Ö¾Öê¤ü−Ö,
ÃÖæ“Ö−ÖÖ‹Ñ, ×¾Ö¾Ö¸üÖ µÖÖ †−µÖ ¤üÃŸÖÖ¾Öê•Ö µÖÖ úÖê‡Ô ¿Öã»ú ¯Öê™ëü™ü úÖµÖÖÔ»ÖµÖ êú êú¾Ö»Ö ˆ¯ÖµÖãŒŸÖ úÖµÖÖÔ»ÖµÖ ´Öë Ã¾ÖßéúŸÖ ÆüÖëÖê …
¿Öã»ú: ¿Öã»ú µÖÖ ŸÖÖê −Öú¤ü ºþ¯Ö ´Öë µÖÖ "Controller of Patents" êú −ÖÖ´Ö ´Öë ¤êüµÖ ²Öïú ›ÒüÖ°™ü µÖÖ “Öêú êú «üÖ¸üÖ ³Öê•Öß •ÖÖ ÃÖúŸÖß Æîü •ÖÖê ˆÃÖß Ã£ÖÖ−Ö êú ×úÃÖß
†−ÖãÃÖæ×“ÖŸÖ ²Öïú ´Öë ¯ÖÏ¤ü¢Ö ÆüÖê •ÖÆüÖÑ ˆ¯ÖµÖãŒŸÖ úÖµÖÖÔ»ÖµÖ ÛÃ£ÖŸÖ Æïü…


SPECIAL NOTICE
18 Months publication as required under Section 11A of the Patents Act, 1970
as amended by the Patents (Amendment) Act, 2005.

Notice is hereby given that any person at any time before the grant of Patent may give representation by way
of opposition to the Controller of Patents at appropriate office on the ground and in a manner specified under
section 25(1) of the Patents (Amendment) Act, 2005 read with Rule 55 of the Patents (Amendment) Rules,
2006.
Notice is also given that if any interested person requests for copies of the complete specification, drawing
and abstract of any application already published, the photocopy of the same can be supplied by the Patent
Office as per the jurisdiction on payment of prescribed fees of Rs.4/- per page. If any further details are
required to be obtained, the same can be provided by the respective Patent Offices on request.

(P H Kurian)


SPECIAL NOTICE

Under the new provision of the Patents Act, 1970 as amended by the Patents (Amendment) Act,
2005 and Rules there under, Publication of the matter relating to Patents in the Official Gazette of India Part
III, Section 2 has been discontinued and instead “The Official Journal of the Patent Office” is being
published containing all the activities of The Patent Office such as publication of all the patent applications
after 18th months , grant of patents & all other information in respect of the proceedings as required under
the provisions of the Patents (Amendment) Act, 2005 and Rules thereunder on weekly basis on every
Friday.

The Journal is uploaded in the website every Friday. So Paper form and CD-ROM form of the Journal are
discontinued from 01/01/2009.

SPECIAL NOTICE
Every effort is being taken to publish all the patent applications under section 11(A) of the Patents Act.

However, if duplication of publication of any application is found, then earlier date of publication will be

taken for the purpose of provisional protection for applicant and Patent Office will grant Patent not before

six months from the date of second publication, provided that there is there is no third party representation.


PUBLICATION U/S. 87(1)
The Compulsory licence Application No. C.L.A. No. 1 of 2011
from M/S. Natco Pharma Ltd. In Patent No. 215758 is hereby published

(P H Kurian)

FORM 17

THE PATENTS ACT, 1970
(39 of 1970)
&
THE PATENT RULES, 2003

APPLICATIONFORCOMPULSORYLICENCE
[See sections 84(1), 91, 92(1) or 92A; rule 96]

We, NATCO PHARMA LIMITED, of NATCO House, Road No 2, Banjara Hills, Hyderabad 500 033, Andra
Pradesh, India;

hereby apply for the grant of a compulsory licence under Patent No. IN 215758, (formerly
IN/PCT/2001/00799/MUM), dated 28.03.2008, granted to BAYER CORPORATION of 100 Bayer Road,
Pittsburgh, PA-15205-9741, USA on the following grounds namely:-

As enclosed herewith

We declare that the facts and matters stated herein are true to the best of my knowledge, information
and belief.

The details of the documentary evidence in support of my/our interest and the grounds stated above
are given below:

As enclosed herewith

Our Address for service in India is, Rajeshwari and Associates, 1039, First Floor, C- Block, Sushant Lok-I,
Gurgaon -122002, Haryana, India


BEFORE THE CONTROLLER OF PATENTS, MUMBAI

I N THE MATTER OF:

Natco Phartna Limited ... APPUCANT/PETITIONER

VERSUS

Bayer Corporation ... RESPONDENTIPATENTEE

APPLICATION UNDER SECTION 84(1) OF THE PATENTS ACT, 1970
(AS AMENDED) FOR GRANT OF COMPULSORY LICENCE

The Applicant abovenamed humbly submits as under :

1. About the Applicant:
The Applicant herein is a company incorporated under the Companies
Act 1956 and having its registered office at Natco House, Banjara Hills,
Hyderabad. The Applicant was incorporated in the year 1981 and since
then it has been in the business of research, development,
manufacturing and marketing of pharmaceutical substances and
finished dosage forms for Indian and Internationa! markets. From a
humble beginning with 20 employees, the company has grown over the
years into one with more than 2000 employees, including well trained
scientists and researchers. The Applicant Company's core area of
expertise lies in manufacture and development of anti-cancer drugs.


Further details about the Applicant are set out and explained later in
the present application.

2. Subject matter of the present application:
The present application for compulsory licence is being preferred in
respect of a product called 'Sorafenib' which is a compound said to be
covered by Indian patent no. 215758 granted on 03.03.2008 to the
Patentee. It is belived that the active pharmaceutical ingredient
'sorafenib' is covered by this Patent. A copy of the Indian patent
no.215758 granted on 03.03.2008 is annexed herewith at Annexure-
A. The Applicant prays for leave to file certified copy of the Patent in
due course. The said product being an inhibitor of several Tyrosine
protein kinases (VEGFR and PDGFR) and RAf kinase is used for the
treatment of primary kidney and advanced primary liver cancer.
The said product is marketed under the brand name NEXAVAR by the
Patentee. The Nexavar cost of therapy per month is
Rs.2,80,428/-. A copy of the product label of Nexaver is annexed
herewith as Annexure-B.

3. Hepatocellular Carcinoma Fact Sheet

A. The Disease
Hepatocellular carcinoma (HCC), also known as primary liver cancer, js
the most common form of liver cancer and is responsible for 80 percent
of the primary malignant liver tumors observed in adults (source:
World Cancer Report, 2008 IARC Press 2008, page 180 to 185 is
annexed herewith as Annexure-C). For patients diagnosed with HCC
the prognosis is poor because symptoms usually do not appear until a
late stage in the disease (A print out of the hyperlink Mayo Clinic,


http://www.mayoclinic,com/heath/liver-cancer/DS00399/DSECTION=
treatments-and-drugs is annexed herewith as Annexure-D) In other
words, most cases of HCC are detected only at a very (late stage.
B. Key Statistics
• HCC is the fifth most common cancer worldwide (source: page
180) with a five-year relative survival rate of about seven
percent.
• HCC disproportionately affects men, with four times as many men
developing HCC as women.
• HCC causes more than 700,000 deaths annually worldwide.
• In 2008 approximately 20,144 cases of HCC were reported in
India, and more than 18,043 Indians died of HCC;
The above information has been obtained from the following
sources, copies of which are annexed hereto as Annexure-D. E.
F, respectively:
1) Mayo Clinic Report.
2) World Cancer Report 2008 IARC Press, 2008 (page 224 to
229).
3) GLOBOCAN 2008: Cancer Incidence, Mortality and
Prevalence India, IARC Press, 2008.

4. Renal Cell Carcinoma Fact Sheet

A. The Disease
. Renal cell carcinoma (RCC) is the most common type of kidney
cancer in adults, causing 85 percent of all kidney cancers, (source:
American Foundation for Urologic Disease is annexed hereto as
Annexure-G)


• Despite advances in understanding the growth mechanisms of
many different tumor types, kidney cancer is still not fully
understood. It is believed that both the Ras signaling pathway and
angiogenesis may play a role in kidney cancer,

B. Key Statistics
• Kidney cancer disproportionately affects men, with roughly twice as
many men as women developing the disease annually.
• The risk of kidney cancer increases with age. Over 90 percent of
cases are diagnosed after age 45. The average age among newiy-
diagnosed kidney cancer patients is 66, (source; Harvard Center for
Cancer Prevention. Your Disease Risk: Kidney Cancer. Available at:
http://www,diseaseriskindex.harvard.edu/update/hccpquiz.pl?lang =
english&func=show&quiz=kidney&page=fact sheet)
• At the time of diagnosis, normally the cancer has already
metastasized (spread to distant body locations) in about one-third
of people with kidney cancer, (source: American Foundation for
Urologic Diseases)
• For patients with early-stage kidney cancer, the five-year survival
rate is between 70 and 98 percent (source: Globocon 2008). In
later-stage disease, when the cancer has metastasized, the five-
year survival rate is between 15 and 18 percent, (source: American
Foundation for Uroiogical Diseases)
• In 2008, about 8,900 Indians were diagnosed with kidney cancer,
and about 5,733 died from the disease, (source: Harvard Center for
Cancer Prevention. Your Disease Risk: Kidney Cancer, Available at:
http://www.diseaseriskindex.harvard.edu/update/hccpquiz.pl?lanq=
engiish&func=show&quiz = kidney&paqe=fact sheet) (source:


GLOBOCAN 2008: Cancer Incidence, Mortality and Prevalence in
India IARC Cancer IARC Press, 2008)

The above information has been collected from the following
sources, copy of which are annexed hereto as Annexure-G and
Annexure-H respectively:
i) American Foundation for Urologic Diseases.
ii) Harvard Center for Cancer Prevention. Your Disease Risk: Kidney
Cancer. Available at:
http://www,diseaseriskindex.harvard.edu/update/hccpquiz.pl?la
ng-enqlish&func=show&quiz-kidney&page=fact sheet.

5. Position in India:

It is submitted that at this point to the knowledge of the Petitioner,
who has been in this field of treating cancer patients for over 20 years,
there are at least 1,00,000 patients in India suffering from different
forms and types of renal cell carcinoma and hepatic cell carcinoma, On
an average, about 30,000 patients are diagnosed every year and
added to the patient pool. Over 24000 patients die in India every year
on account of these diseases.

6. Treatment.

Treatment-Liver Cancer
•• Treatment options for HCC depend on the stage of the malignant
disease, underlying liver function, which is a determinant of the
usually co-existing cirrhosis, as well as the patient's overall condition.
•• The three main types of treatment for liver cancer are surgery
(including liver transplantation), locoregional treatment modalities and


chemotherapy. Sometimes two or more of these methods are
combined.
Surgery offers the only chance to treat liver cancer. If the cancer is
found at an early stage and the rest of the liver is healthy, surgery
with or without liver transplantation may be curative, However, only
about 15% of patients have resectable disease' (source: Cancer
Research UK, http://www.cancerhelp.org.uk/help/defauit.asp?
page=4917#chemo which is annexed hereto as Annexure-I) Even
after surgery the five-year survival rate is only about 30 to 40 percent.

Treatment - Kideny Cancer
•• The treatment of RCC depends on the severity of the cancer and
the patient's overall health.
The primary therapy for kidney cancer is surgery, which is effective
only when all of the cancer is removed. Radiation treatment is also
used when the cancer has spread beyond the kidney, (source:
American Foundation for Urologic Disease)
Immune modulators, such as interferon-alpha and interleukin-2 (IL-
2), are sometimes used, but response rates remain relatively low
with these treatments (source: American Cancer Society. Detailed
Guide: Kidney Cancer. Available at:
http://www.cancer.org/Cancer/KidneyCancer/DetailedGuide/index
printout is annexed hereto as Annexure-J)
•• Chemotherapy - in some cases, since kidney cancer is resistant to
chemotherapy.
• Several newer forms of therapy that target specific parts of cancer
cells have been used to treat people with advanced kidney cancer.
These include drugs that stop angiogenesis (new blood vessel


growth) and drugs that target other important cellular growth
factors. One of such drugs is Sorafenib tosylate.

Sorafenib:
Sorafenib is prescribed by the physician, it is administered as 200mg
tablet and the dosage per day is 800mg. which translates to two tablets
in the morning and two tablets in the night. The tablets must be
consumed till the tumor progression/ intolerable toxicity. Normally,
patients with renal carcinoma may be covered and may receive
insurance cover for nephrectomy; however patients do not receive any
cover/assistance from Insurance companies for the use of the drug
Sorafenib. The drug Sorafenib has to be taken by the patient
throughout his lifetime,

Treatment of diseases - Renal cell carcinoma and hepatic cell
carcinoma.
Drug - Sorafenib Tosylate.
Dosage - 400 mg, twice a day (4 tablets a day).
Duration of treatment - Lifetime.
Price - Rs,2,80,428 per month per patient.
Insurance - Nil.

Survival rate:
The survival rate in case of renal and hepatic carcinoma depends
entirely on the stage of the disease. In advanced metastatic renal
carcinoma, the survival rate is extremely poor and patients may live for
few months to 3-5 years. Hepatic cell carcinoma is even worst with a
survival rate of less than 10% and life span of not more than 12
months.


From the above it is clear that the product Sorafenib which is the
subject of the present application is drawn to treat a gruesome disease
that hardly has a cure and patients afflicted by this deadly disease if
put on Sorafenib, must be given this treatment for their entire lifetime
and should be able to access this drug irrespective of their caste, creed,
affordability etc.

7. The Patentee and Sorafenib:
Sorafenib- limited availability: It is submitted that the product
Sorafenib is exhorbitantly priced and limited in availability in India as
explained below:
a) Product imported: It is learnt that the Patentee Bayer Corporation
imports and sells the drug sorafenib in India. To the knowledge of
the Applicant, this product is not manufactured in India by the
Respondent, The price of each tablet is Rs2337, As stated earlier,
the average requirement per patient per month is about 120
tablets which works out to about Rs 2,80,428/- month and about
Rs 33,65,136/- per year. Thus the product is exhorbitantly priced
and almost out of reach of most of the people in India.

b) Limited availability: The said product is available in pharmacies
attached to certain hospitals and that too only in metro cities such
as Mumbai, Chennai, Kolkata and Delhi. The product is often out of
stock or not available in common pharmacies even in metro cities
and in second tier or other smaller cities in India. Hence the
product sold by the Patentee is extremely highly priced and is
limited in availability. Currently, to the Bayer is operating with 12
distributors in India. To the knowledge of the Applicant, the
Distributors are in Delhi, U.P., Punjab, Gujarat, West Bengal, Bihar,
Vardman, Kerala and Tamil Nadu. There are no distributors atleast


in the states of Madhya Pradesh, Jammu and Kashmir, Orissa,
Rajasthan, Haryana, Chhattisgarh, Uttarakhand, Jharkhand,
Himachal Pradesh, Assam, Arunachal Pradesh, Manipur, Meghalaya,
Mizoram, Nagaland, Sikkim, Tripura, Rest of Maharastra, Goa,
Pondicherry.

c) It is estimated that though the Patentee sells the product, it
reaches less than 1% of patients and almost 99 % of patients who
are unable to afford the drug are left to die every year.

According to GLOBOCAN data at least 30,000 patients are
diagnosed every year who suffer from Liver and Kidney cancer. It
is estimated that nearly 1,00,000 patients are currently suffering
in India on these diseases. Of these, less than 1% of patients
are catered to by the Rspondent Bayer. The remaining 99% of
the patients do not receive any medication and thereby fall victim
and die on account of this dreaded diseases.

d) Requirement Vs. Availability
As stated earlier, the approx member of patients in India suffering
from RCC &. HLC is about 1,00,000. Since the prescribed regimen is
2 tablets a day, the total requirement per month = 120 tablets.
Bayer does not manufacture the product Sorafenib in India. The
number of Sorafenib tablet in the market is far less than the
requirement under demand for the patients.

e) Product Sorafenib found to be expensive in UK and US: It is
important to note that in the UK, the National Health Service often
subsidizes the price of important pharmaceuticals products such as


those used for treatment of cancer. The NHS, after going
through
the price of Nexavar [which in UK works out to about
£2504,60]
and the schemes offered by the Patentee [buy 3 and get one
free]
found that the price of Nexavar is too expensive and NHS
decided
not to sponsor or subsidize the said drug under its schemes.
The
relevant information is available at the url:
(source:
http://www.advfn.com/nasdaq/StockNews.asps?stocknews
=ONXX&article=40430330&headline=uk-watchdog-says-
bayer-liver
-drug-nexavar-too-expensive, a printout of which is annexed
hereto as Annexure-K)

Similarly, in US, the product Nexavar is not subsidized by any
authority and the price is about USD 4300per month.

S. Conclusion:
In view of the above analysis, the Applicant submits that :
a) more than three years from the date of grant of the patent no
215758 have elapsed [the patent was granted on 03-03-2008]
and yet, the patentee Bayer has not taken adequate steps to
manufacture in India and make full use of the invention;
b) a prima facie case of reasonable requirements of the public
not
being satisfied is deemed to be made out because :
i) the number of people who need access to the product
Sorafenib to prolong their life or improve their health
significantly exceeds those with actual access to the drug
(60
-Vs- 3000)[1-% vs. 99%], and
it) a substantial barrier to access the product is price;
(Rs.2,80,482 per month)


It is in these circumstances that the present application for
compulsory licence is being preferred.

9. Applicant's interest:
a) As stated in the foregoing paragraphs, the Applicant herein is a
pharmaceutical company engaged in the manufacture of several
anti-cancer products for last 20 years. Some of the products
manufactured by the Applicant include Imatinib, Geftinib,
Lenalidomide, etc,

b) Why the Applicant prays for grant of compulsory licence:
The Applicant herein submits that they have been performing
research and development of various anti-cancer drugs. The
applicant having known the plight of the cancer patients and the
difficulties facilities faced by them, has decided to develop,
manufacture and sell the said product Sorafenib to such needy
patients irrespective of their location in India, at the lowest
possible price so that access and availability of the drug is
improved,The Applicant submits that this project is being
undertaken is absolute bonafides, without any oblique
commercial motives whatsoever.

10. Capability of the Applicant: The Applicant submits that as
stated earlier, the Applicant is one of the foremost and leading
pharmaceutical companies in India. The Applicant has its own
manufacturing and marketing strengths as detailed below:

a. Recognition of the R&D facilities:


The Applicant submits that its R&D facilities conform to the

strictest standards adopted anywhere in the world. All the

facilities are GMP certified, and the Applicant follows GMP

practices as prescribed by the US FDA for both API and

Formulation. (Copies of Awards and Certificates are produced

herewith as Annexure-L)

b. Facilities to manufacture sorafenib:

In so far as the product Sorafenib is concerned, the Applicant

herein does have the requisite technical know-how to develop

and manufacture the product Sorafenib on a large scale. The

Applicant herein has applied and obtained a patent for a process

of producing sorafenib, copy of which is annexed herewith as

Annexure-M. The applicant submits that it can manufacture the

product sorafenib by employing the existing facilities and does

not require any additional plant/machinery or investment for the

same since the Applicant is already manufacturing other anti

cancer products.

c. Ability of Applicant to market the product:

The Applicant submits that they do have the abilities and

capabilities to manufacture the product Sorafenib (should the


licence be granted) and cater to the needs and necessity of the

entire population suffering from rena! cancer and/or hepatic cell

carcinoma.

d. Proposed Capacity:

The Applicant can manufacture the product at the rate of

20,00,000 tablets a day, amounting to about 6,00,00,000

tablets per month. There is a need for supply of 4,80,000 tablets

a month, which this Applicant can easily manufacture and

supply.

e. Proposed Price:

The Applicant proposes cost of about Rs 74/- per tablet,

working out to Rs 8,880/- per month for treatment to a patient.

The Applicant is also ready and willing to manufacture and offer

for free the tablets to patients who cannot afford even the

proposed price.

f. Marketing / Distributor Network:

The Applicant has already obtained approval from the Drug

Controller General of India for manufacture and marketing of the

product Sorafenib in India. A copy of the license granted is


annexed herewith as Annexure-N.Hence, the Applicant has the

potential to manufacture and market the drug in India.

The Applicant is already supplying anti cancer products to

various hospitals all over India. Its drugs are found with almost

all of the chemists all over India. The Applicant has the

distribution network in almost every city in India including all the

districts in the country. The Applicant is ready and willing to

furnish details of its distributors if so called for by the Learned

Controller.

11. Efforts by Applicant to obtain voluntary licence:

The Applicant herein had made independent efforts to obtain licence to

manufacture and sell the product Sorafenib in India and by virtue of

letter dated 06th Dec 2010, the Applicant had requested the patentee

for such licence. The Patentee refused the same vide letter dated 27th

Dec 2010. The copies of the said letters dated 06th December 2010 and

dated 27th December 2010 are annexed herewith as Annexure-O and

Annexure-P respectively.

12. The grounds for grant of licence

The Applicant submits that in view of the facts and circumstances

described above, a prima facie case that reasonable requirements of


the public not being satisfied and for grant of compulsory license
is made out because:

a. the Applicant herein had made a request for licence which
was turned down and refused by the Patentee point blank,
without any discussion whatsoever, and on account thereof,
establishment of a new trade or industry for supply of
Sorafenib to needy patients is severely hampered;

b. as explained above, the number of patients and the actual
demand in the market for Sorafenib far exceeds the supply
thereof by the Patentee and hence the demand for the
patented product has not been met to an adequate extent;

c. as explained above, the price of the patented product
Sorafenib is too high and simply unaffordable by the common
man making the product inaccessible and out of reach- hence
the demand for the patented product has not been met on
reasonable terms;


d. the Applicant bonafidely believes that the market for export
of the drug to developing and under-developing countries is not
being supplied or developed;

e. on account of refusal of the licence, the establishment of
commercial activities in India in respect of the patented
product and supply thereof to needy patients is totally
prejudiced;

f. the patented product is being imported into India by the
Patentee and is not manufactured within India- hence the
product is not worked in the territory of India to the fullest
extent that is reasonably practicable;

g. the patented product is available in limited quantities and
that too only in certain select places in certain cities - hence the
product is not worked in the territory of India to an adequate
extent or not worked to the fullest extent that is reasonably
practicable;


h. the working of the patented product in India is hindered in India

due to importation of the patented product from abroad by the

patentee and those claiming under him.

i. The practice adopted by the Patentee of exorbitantly pricing its

patented life-saving product is abuse of its monopolisitic rights

and such practice is unfair and anti-competitive;

13. The Applicant craves leave to submit certified copies of the Patent

document IN 215758 in due course and any other documents as may

be called for by this office.

14. The terms:
After adjudication, should the learned Controller decide to grant
compulsory licence in favour of the Applicant herein, the Applicant is
prepared to accept the same on the following terms:
a, the right to manufacture and sell Sorafenib shall be limited to
the territory of India- the Applicant shall not use the licence for
sale to other countries. Aplicant shall take all necessary steps to
ensure that the product is sold and available only within the
territory of India. All products under the Licence shall be marked
specifically that they are for sale and use in India only;
b, the products under licence shall be manufactured only to cover
patients who are afflicted by renal and hepatic carcinoma :
preferance shall be given to patients who are economically weak,
government welfare schemes and those in backward areas ;


c. the Applicant agrees to pay a royalty to the Patentee at the
rate as fixed by the Ld Controller;
d. Applicant agrees to make available the patented product at
the most reasonable and affordable price possible. Initially
the applicant proposes a price of Rs 74 per tablet which
works out to Rs 8880 /- for month for the treatment.
e. Agrees to offer the drug free of cost to deserving and needy
for
their lifetime.

The Applicant agrees to be bound by any other terms and
conditions as may be imposed by the Ld Controller.

15. C.S. (OS) No.1090/2011.
It is submitted that the Respondent Bayer Corporation, has filed
Civil Suit No. 1090/2011 in the High Court of Delhi against the
Applicant alleging infringement of Patent No.215758. The present
application has been filed without prejudice to the contentions,
rights and liberties of this Applicant in the said suit.

16. In view of the above submissions, the Applicant humbly
prays that:
a) the Ld Controller may be pleased to grant and issue
Compulsory licence in favour of the applicant herein in
respect of Indian patent no 215758 upon terms and conditions
that the Ld Controller may deem fit and proper in the
circumstances of the case;


(iii) such other or further reliefs be granted to meet the
ends of justice.

VERIFICATION

Verified at Delhi on this 18th day of july,2011 that the contents
of the Reply are based on legal advise received and believed to
be true (save and except fact for which I have relied on matters
of record). No part of it is false and nothing material has been
concealed therefrom.

CONTINUED TO PART-2


CONTINUED FROM PART- 1

Early Publication:
The following patent applications have been published under section 11A (2) of The Patents (Amendment) Act 2005 and rule
24A of The Patents (Amendment) Rules, 2006. Any person may file representation by way of opposition to the Controller of
Patents at the appropriate office against the grant of the patent in the prescribed manner under section 25(1) of the Patents
(Amendment) Act 2005 read with the rule 55 of The Patents (Amendment) Rules, 2006:
(12) PATENT APPLICATION PUBLICATION (21) Application No.386/DEL/2011 A
(19) INDIA
(22) Date of filing of Application :15/02/2011 (43) Publication Date : 12/08/2011

(54) Title of the invention : AN IMPROVED PLANT FOR PREPARING SYNTHETIC GYPSUM.

(51) International classification :C04B (71)Name of Applicant :
(31) Priority Document No :NA 1)SHREE CEMENT LIMITED
(32) Priority Date :NA Address of Applicant :BANGUR NAGAR, BEAWAR
(33) Name of priority country :NA 305901, DISTT. - AJMER, RAJASTHAN, INDIA. Rajasthan
(86) International Application No :NA India
Filing Date :NA (72)Name of Inventor :
(87) International Publication No :NA 1)H.M. BANGUR
(61) Patent of Addition to Application Number :NA
Filing Date :NA
(62) Divisional to Application Number :NA
Filing Date :NA
(57) Abstract :
The present invention relates to an improved plant for preparing Synthetic gypsum.

No. of Pages : 12 No. of Claims : 8


(19) INDIA

(54) Title of the invention : A NOVEL PHARMACEUTICAL COMPOSITION OF CEFPODOXIME AND OFLOXACIN TO
TREAT MICROBIAL INFECTIONS

(51) International classification :C02F (71)Name of Applicant :
(31) Priority Document No :NA 1)AKUMS DRUGS & PHARMACEUTICALS LIMITED
(32) Priority Date :NA Address of Applicant : 304, MOHAN PLACE, LSC, BLOCK-
(33) Name of priority country :NA C, SARASWATI VIHAR, DELHI-34. Delhi India
(86) International Application No :NA (72)Name of Inventor :
Filing Date :NA 1)MR. SANJEEV JAIN
(87) International Publication No :NA
Filing Date :NA
Filing Date :NA
(57) Abstract :
The present invention discloses a pharmaceutical formulation comprising Cefpodoxime and Ofloxacin for the treatment of variety of
bacterial infections. The present invention exhibits a broad spectrum activity, thereby effective against a number of microorganisms.



(12) PATENT APPLICATION PUBLICATION (21) Application No.1120/MUM/2011 A
(19) INDIA

(54) Title of the invention : A SYSTEM AND METHOD FOR FACILITATE DOMAINS AND USERS, APPLICATIONS,
SERVICES, OBJECTS, COMMUNICATION CHANNELS OF MULTIPLE DOMAINS TO COMMUNICATE WITH EACH
OTHERS.

(51) International classification :G06F17/00 (71)Name of Applicant :
(31) Priority Document No :NA 1)RATHOD YOGESH CHUNILAL
(32) Priority Date :NA Address of Applicant :1502/A MAHAVIR RESIDENCY, L B
(33) Name of priority country :NA S MARG, NEAR BALRAJESHWAR MANDIR, MULUND(W),
(86) International Application No :NA MUMBAI 400080, MAHARSHTRA, INDIA
(87) International Publication No :N/A 1)RATHOD YOGESH CHUNILAL
Filing Date :NA
Filing Date :NA
(57) Abstract :
A system and method for facilitate users of multiple domains to communicate with each other is described. A method includes multi
domain communication capable domains including social network enables users to post or share contents to other multi domain
communication capable domains or external domains, users, applications, services, objects, devices, databases of external domains
and/or present domain. Users may select how content will be published and control the accessibility of uploaded content using a
privacy setting for each content item that the user posts. The privacy setting defines, or identifies, the set of external domains
including web sites, applications, services, devices, networks, groups, objects, widgets, web pages and connections or users of present
network who may view the posted content item. The posted content item is placed in a particular web pages, applications, services,
objects, communication channel in the social network, such as video sharing, question and answer application, updated status, photo
albums, search engine, deals application, e-commerce service, mobile service where the content item can be viewed by those who are
permitted to view it according to its associated privacy setting. Varying granularities of privacy settings provide flexibility for content
accessibility on a social network and external domains.



(19) INDIA

(54) Title of the invention : A SYSTEM AND METHOD FOR O-MAIL OR OMNIPRESENT COMMUNICATION, O-MAIL
ADDRESS, O-MAIL SERVICE, O-MAIL CLIENT, O-MAIL SERVER, NETWORK, PLATFORM AND PIN POINT
COMMUNICATION PROTOCOL (PPP)

(51) International classification :G06F17/00 (71)Name of Applicant :
(31) Priority Document No :NA 1)RATHOD YOGESH CHUNILAL
(32) Priority Date :NA Address of Applicant :1502/A MAHAVIR RESIDENCY, L B
(33) Name of priority country :NA S MARG, NEAR BALRAJESHWAR MANDIR, MULUND (W),
(86) International Application No :NA MUMBAI 400080, MAHARASHTRA, INDIA
(87) International Publication No :N/A 1)RATHOD YOGESH CHUNILAL
Filing Date :NA
Filing Date :NA
(57) Abstract :
A system and method for new O-Mail communication protocol, service is described. A method includes system, method, protocol,
service, platform, and framework for facilitating anybody can communicate with anybody, anywhere for anything and provide on
demand, integrated, unified, loosely coupled, user friendly, personalize, customize, contextual, interconnected, dynamic, real time
communication, collaboration and sharing platform based on O-Mail or omnipresent communication, O-Mail address, O-Mail service,
O-Mail client, O-Mail Server, network, platform and pin point communication protocol (PPP). A method also includes multi domain
communication capable domains including social network enables users to post or share contents to other multi domain
communication capable domains or external domains, users, applications, services, objects, devices, databases of external domains
and/or present domain. Users may select how content will be published and control the accessibility of uploaded content using a
privacy setting for each content item that the user posts. The privacy setting defines, or identifies, the set of external domains
including web sites, applications, services, devices, networks, groups, objects, widgets, web pages and connections or users of present
network who may view the posted content item. The posted content item is placed in a particular web page, applications, services,
objects, communication channel in the social network where the content item can be viewed by those who are permitted to view it
according to its associated privacy setting. Varying granularities of privacy settings provide flexibility for content accessibility on a
social network and external domains.



(19) INDIA

(54) Title of the invention : PROCESS FOR PREPARATION OF ALKALI METAL IODIDE.

(51) International classification :C25B1/24 (71)Name of Applicant :
(31) Priority Document No :NA 1)OMKAR SPECIALITY CHEMICALS LTD.
(32) Priority Date :NA Address of Applicant :B-34, M.I.D.C., BADLAPUR (E),
(33) Name of priority country :NA DIST-THANE 421503, MAHARASHTRA, INDIA.
Filing Date :NA 1)MR. OMKAR PRAVIN HERLEKAR
(87) International Publication No :N/A
Filing Date :NA
Filing Date :NA
(57) Abstract :
The mentioned is a three step process for preparation of alkali metal iodides particularly to sodium iodide and potassium-iodide. In
first step of reaction, ammonium compounds like ammonium hydroxide, ammonium carbonate and ammonium bicarbonate and iodine
are reacted with each other in presence of catalyst like hydrogen peroxide or hydrazine hydrate to form ammonium iodide. In second
step, reaction between alkaline hydroxide or carbonate or bicarbonate with ammonium iodide takes place to form alkali metal iodide.
Evaporation of the obtained solution to form crystals of sodium or potassium iodide in last step.



(19) INDIA

(54) Title of the invention : MULTITHERAPEUTIC NUTRACEUTICAL COMPOSITION OF GANODERMA LUCIDUM

(51) International classification :A61K36/00 (71)Name of Applicant :
(31) Priority Document No :NA 1)DR. ALKA PRAVIN JAJOO
(32) Priority Date :NA Address of Applicant :DEPARTMENT OF
(33) Name of priority country :NA BIOTECHNOLOGY SGB AMRAVATI UNIVERSITY
(86) International Application No :NA AMRAVATI, 444 602 Maharashtra India
(87) International Publication No :N/A 1)DR. ALKA PRAVIN JAJOO
(61) Patent of Addition to Application Number :NA 2)PROF MAHENDRA KUMAR RAI
Filing Date :NA 3)MS SHARADA LAXMAN DEORE
(62) Divisional to Application Number :NA 4)MR. BHUSHAN A. BAVISKAR
Filing Date :NA
(57) Abstract :
Gonoderma lucidum is a basidiomycete while rot macrofungus which has been used extensively as Elixir of eternal youth in China,
Japan, Korea and other Asian countries for more than 2000 years. A great deal of work has been carried out on therapeutic potential of
Gonoderma htcidum. The basidiocarp, mycelia and spores of Gonoderma lucidum contain approximately 400 different bioactive
compounds, which mainly include iriterpenoids. polysaccharides, nucleotides, sterols, steroids, fatty acids, proteins/peptides and trace
elements which has been reported to have a number of pharmacological effects including immunomodulation. anti-atherosclerotic,
anti-inflammatory, analgesic, chemopreventive. antitumor chemo and radio protective, sleep promoting, antibacterial, antiviral
(including anti-HIV), hypolipidemic, anti-ftbroiic. hepatoprotective, anti-diabetic, anti-androgenic, anti-angiogenic. anti-herpetic.
antioxidative and radical-scavenging, anti-aging, hypoglycemic, estrogenic activity and anti-ulcer properties. Gonoderma lucidum has
now become recognized as an alternative adjuvant in the treatment of leukemia. carcinoma, hepatitis and diabetes. The invention
relates 10 the multitherapeutic nutraceulical composition of Gonoderma lucidum as extract and juice and method of use of the same in
enhancing the immunity of healthy as well as immune compromised people. The compositions are also used to alleviate age relaled
diseases. The invention also provides Gonoderma lucidum composition in a ready-to-drink form comprising the water soluble
polysaccharides and alcohol soluble triterpenoids both therapeutically responsible constituents.



(12) PATENT APPLICATION PUBLICATION (21) Application No.1333/CHE/2010 A
(19) INDIA

(54) Title of the invention : AN HERBAL PAINT COMPOSITION AND MEHTOD OF PREPARATION THEREOF

(51) International classification :C09D (71)Name of Applicant :
(31) Priority Document No :NA 1)S.AMUTHA
(32) Priority Date :NA Address of Applicant :7, N.K.CHETTY
(33) Name of priority country :NA STREET,PUDUPET,GUDIYATTAM-632602 Tamil Nadu India
Filing Date :NA 1)S.AMUTHA
(87) International Publication No : NA
Filing Date :NA
Filing Date :NA
(57) Abstract :
The present invention relates to an herbal paint composition. The said herbal paint composition shows improved paint characteristics
such as shine, grip and the like, simultaneously proving to be a potent insect and pest resistant, wood-corrosion resistant, eco-friendly
with no harmful side effects. The present invention also relates to a method of preparation of the said herbal paint composition



(19) INDIA

(54) Title of the invention : HERBAL PAIN REMOVER OIL COMPOSITION AND METHOD OF PREPARATION

(51) International classification :A61K31/00 (71)Name of Applicant :
(31) Priority Document No :NA 1)S. AMUTHA
(32) Priority Date :NA Address of Applicant :7, N.K. CHETTY STREET,
(33) Name of priority country :NA PUDUPET, GUDIYATTAM - 632602 Tamil Nadu India
Filing Date :NA 1)S. AMUTHA
Filing Date :NA
Filing Date :NA
(57) Abstract :
The present invention provides a herbal oil based composition prepared from a blend of herbs and essential oils that comprises
Camphor Oil, Menthol Oil, Homa Slat Oil (Thymol Oil), Bamboo Salt and Thipili (Piper longum) The herbal oil based composition in
accordance with the present invention is effective in curing common aches and pains like headaches, back pain and others such as
asthma, inflammation and the like. The herbal composition provides relief and removes pain by topically applied it on the area
required to be treated. The present invention also provides a method for the preparation of the said herbal pain remover oil
composition.



(19) INDIA

(54) Title of the invention : LIGHTING FOR SPORTS STADIUMS AND OUTDOOR ARENAS

(51) International classification :F21S2/00 (71)Name of Applicant :
(31) Priority Document No :NA 1)K. Vishweswar Reddy
(32) Priority Date :NA Address of Applicant :35 Sai Enclave Avenue 1 Road No. 12
(33) Name of priority country :NA Banjara Hills Hyderabad Andhra Pradesh Andhra Pradesh India
Filing Date :NA 1)K. Vishweswar Reddy
Filing Date :NA
Filing Date :NA
(57) Abstract :
A lighting system for illuminating large spaces which uses tethered lighter than air balloons with LEDs mounted on its lower surface
facing the ground. There are several such lighter than air balloons with LEDs tethered around the ground and floating high above.
Each of the balloons is tethered by two or more tethering ropes to avoid movement due to wind. Such a lighting system is easy to
deploy, does not require permanent structures, is transportable and relatively lower in cost.



(19) INDIA

(54) Title of the invention : SELF-CENTERING WHEEL ARRESTING AND LIFTING MECHANISM FOR MULTILEVEL
VEHICLE PARKING SYSTEM

:B60S, (71)Name of Applicant :
(51) International classification
E04H6/06 1)Mr. K. T. Jose
(31) Priority Document No :NA Address of Applicant :Kulangara House South attara
(32) Priority Date :NA Kokkunnu(via) Mookkannur P.O 683577 Ankamaly Kerala
(33) Name of priority country :NA Kerala India
Filing Date :NA 1)Mr. K. T. Jose
Filing Date :NA
Filing Date :NA
(57) Abstract :
In view of the foregoing, an embodiment herein provides a self-centering unit on a collection-delivery rack of a parking system for
secure arresting of wheels of a vehicle. Specifically, the self-centering unit includes a plurality of wheel-arresting rods that can fold
and unfold with the help of hydraulic jackeys. The movement of a pair of wheel-arresting rods is relative to one another and as these
rods unfold towards the wheel, the self-centering unit not only centers the wheel automatically but also securely arrests the wheel and
lifts the vehicle off the ground.



(19) INDIA

(54) Title of the invention : PREPARATION OF 2-(4-BROMOPHENYL)-2-METHYLPROPANOIC ACID

(51) International classification :C07C17/00 (71)Name of Applicant :
(31) Priority Document No :NA 1)DIVI'S LABORATORIES LIMITED
(32) Priority Date :NA Address of Applicant :7-1-77/E/1/303, DIVI TOWERS,
(33) Name of priority country :NA DHARAM KARAN ROAD, AMEERPET, HYDERABAD - 500
(86) International Application No :NA 016 Andhra Pradesh India
(87) International Publication No : NA 1)MURALI KRISHNA PRASAD DIVI
(61) Patent of Addition to Application Number :NA 2)GUNDU RAO PADAKANDLA
Filing Date :NA 3)NAGWESWARA RAO BOLNENI
(62) Divisional to Application Number :NA 4)KRISHNAJI RAO MUTYALA
Filing Date :NA
(57) Abstract :
Preparation of 2-(4-Bromophenyl)-2-Methylpropanoic Acid Selective bromination of 2-methyl-2-phenylpropanoic acid in aqueous
medium is described to obtain pure 2-(4-bromophenyl)-2-methylpropanoic acid, which is a useful key intermediate in the process of
manufacturing pure fexofenadine.



(19) INDIA

(54) Title of the invention : NEW BARBITURATES OF NITRO AROMATIC COMPOUNDS AS ANTI CONVULSANTS,
HYPNOTIC AGENTS, DYES AND FLUORESCENT MOLECULES

(71)Name of Applicant :
(51) International classification :A61K31/00 1)DR. D. KALAI VANI
(31) Priority Document No :NA Address of Applicant :ASSOCIATE PROFESSOR,
(32) Priority Date :NA DEPARTMENT OF CHEMISTRY, SEETHALAKSHMI
(33) Name of priority country :NA RAMASWAMI COLLEGE, TIRUCHIRAPPALLI - 620 002
(86) International Application No :NA Tamil Nadu India
(87) International Publication No : NA 1)DR. D. KALAI VANI
(61) Patent of Addition to Application Number :NA 2)MS. R. BABY KALA
Filing Date :NA 3)MS. G. MANGAIYARKARSI
(62) Divisional to Application Number :NA 4)MS. V. MANICKKAM
Filing Date :NA 5)MS. G. SRIDEVI
6)MS. R. RAJAMANI
(57) Abstract :
New solid barbiturates of high purity have been synthesized from the ethanolic solution of aromatic nitro compounds (l-chloro-2,4-
dinitrobenzene, l,3-dichloro-4,6- dinitrobenzene or l-chloro-2,4,6-trinitrobenzene) and barbituric acid/thiobarbituric acid / N,N-
dimethylbarbituric acid in the presence of bases such as trimethylamine, triethylamine, tri-n-butylamine, triethanolamine, N,N-
diethylaminoethanol, substituted N,N-dimethylaniline, substituted N,N-diethylaniline, substituted pyridine, substituted quinoline and
l,4-diazabicyclo[2.2.2]octane (DABCO). Spectral charaterisation (uv- vis, ir, pmr, 13C nmr and mass) has been performed on the
synthesized barbiturates. Elemental analysis and other qualitative tests have also been carried out. Single crystal X-ray diffraction
studies have been undertaken with some of the crystalline barbiturates to confirm the structures. Maximal Electro Shock (MES)
method has been employed to examine their anticonvulsant activity. Reduction in extensor phase of convulsion has been noticed for
the synthesized barbiturates. LD50 values of the barbiturates have been assessed in animal model. LD50 values fall under class 4
(>1000 mg/kg) and the animals did not show any sign of acute toxicity and behavioral changes. Therapeutic dose of the new
barbiturates induce hypnosis in albino mice of either sex weighing 25-30 grams. Some of the intensely coloured barbiturates have
fixing ability on cotton, wool and polyester in the presence of mordants. Solid state emission spectra of some of the isolated
barbiturates reveal that they are fluorescent molecules.



(19) INDIA

(54) Title of the invention : A MOBILE ADVERTISING DISPLAY SYSTEM AND A METHOD FOR DYNAMIC TARGETTING
OF LOCATION BASED ADVERTISEMENTS

(51) International classification :G06Q (71)Name of Applicant :
(31) Priority Document No :NA 1)MR. KOPURI AMARNATH
(32) Priority Date :NA Address of Applicant :6-1-1059, FLAT NO.307, TAJ
(33) Name of priority country :NA ENCLAVE, BESIDE SENSATION THEATRE,
(86) International Application No :NA KHAIRATHABAD, HYDERABAD - 500 004 Andhra Pradesh
Filing Date :NA India
(87) International Publication No : NA (72)Name of Inventor :
(61) Patent of Addition to Application Number :NA 1)MR. KOPURI AMARNATH
Filing Date :NA
Filing Date :NA
(57) Abstract :
A mobile advertising display system and method for dynamic targeting of location based advertisements are disclosed. The system
includes a pair of supporting members and a detachable advertisement display panel comprising a front advertisement display and a
rear advertisement display secured to the pair of supporting members. The method includes determining a current location of an
automobile by utilizing a location determination module, utilizing a dynamic data management module positioned at the central
monitoring station for receiving the current location of the automobile, whereby the dynamic data management module
communicatively coupled with a memory module for transmitting the location based advertisement in response to the received current
location of the automobile and enabling a process of dynamic transmission of location based advertisements by the dynamic data
management module to the data communication module for displaying on the display panel elevated above an upper surface of the
automobile.



(19) INDIA

(54) Title of the invention : SYSTEM FOR PROVIDING SUPPLY CHAIN OPERATIONS AS A SERVICE

(51) International classification :G06Q (71)Name of Applicant :
(31) Priority Document No :NA 1)HCL Technologies Ltd.
(32) Priority Date :NA Address of Applicant :50-53 Greams Road Chennai - 600006
(33) Name of priority country :NA Tamil Nadu India.
Filing Date :NA 1)Nipun Kohli
Filing Date :NA
Filing Date :NA
(57) Abstract :
A system for providing supply chain operations as a service in a cloud computing environment across a plurality of tenants comprising
of:-an order management module configured to manage incoming orders and track their status;-a billing module coupled to the order
management module configured to carry out accounting and financial transactions;-a customer ERP module coupled to the service
billing module and order management module configured to manage and implement customer related activities;-one or more service
modules each coupled to the order management module configured to carry out supply chain management activities; and-ne or more
interfaces configured to connect with one or more external entities;



(12) PATENT APPLICATION PUBLICATION (21) Application No.748/KOL/2011 A
(19) INDIA

(54) Title of the invention : A SYNERGISTIC INSECTICIDAL COMPOSITION OF CARTAP HYDROCHLORIDE AND
BUPROFEZIN

(71)Name of Applicant :
(51) International classification :A01N37/00
1)KRISHI RASAYAN EXPORTS PVT. LTD.
(31) Priority Document No :NA
Address of Applicant :FMC FORTUNA, 4TH FLOOR,
(32) Priority Date :NA
BLOCK A-11, 234/3A, A.J.C. BOSE ROAD, KOLKATA-
(33) Name of priority country :NA
700020, WEST BENGAL, INDIA CORPORATE OFFICE 1115,
(86) International Application No :NA
MODI TOWER, 98, NEHRU PLACE, NEW DELHI-110019,
Filing Date :NA
India
(72)Name of Inventor :
1)ATUL CHURIWAL
Filing Date :NA
2)DR. DIPANKAR PATRA
3)ABHISHEK MUKHERJEE
Filing Date :NA
4)DR. BIJAN MAITI
(57) Abstract :
The present invention relates to a Novel insecticidal composition which is effective in controlling insect pests. More particularly, the
present invention relates to insecticidal composition which is prepared by using the two potent insecticides, Cartap hydrochloride and
Buprofezin with some adjuvant and stabilizing agent. Further this composition which displays a synergistically enhanced activity
against insects is useful for controlling plant pests. Moreover this invention relates to the process for the preparation of the above
insecticidal composition. It is particularly effective in combating or preventing insect causing crop loss. These combinations exhibit
synergistic insecticidal activity.



(12) PATENT APPLICATION PUBLICATION (21) Application No.916/KOL/2011 A
(19) INDIA

(54) Title of the invention : AN UNIQUE SYSTEM OF ELECTRIC POWER GENERATION BY THE HELP OF OCEAN TIDAL
ENERGY & GRAVITATIONAL ENERGY

(51) International classification :H02N6/00 (71)Name of Applicant :
(31) Priority Document No :NA 1)RAJ KUMAR BAGH
(32) Priority Date :NA Address of Applicant :6/4, TARACHAND POLLEY LANE,
(33) Name of priority country :NA HOWRAH, WEST BENGAL, PIN-711101 India
Filing Date :NA 1)RAJ KUMAR BAGH
Filing Date :NA
Filing Date :NA
(57) Abstract :
This process will minimize the problem of Electric Power Generation. Combine utilization of Ocean tide and Gravitational force can
generates a huge power by specially design tank and process. From the Sketch-1 we can elastrat the process in brief:- 1. When the
ocean is in high tide position, water from ocean will enter the Primary Tank through Tunnels & lock gate. 2. From Primary Tank the
water will also enter to the Secondary Tank. 3. The secondary tank consist of nos of cylindrical tank with weighted Plungers are fitted
at the top. 4. The outlet pipe from the base of the secondary tank is connected to a common Header through pipe fittings. 5. From
Header, Pipes are connected to Turbine fitted with Alternator. 6. Water from Turbines Outlets discharge to common Channel. 7.
Channel is connected with a Rough Tank through lock gate. 8. From Rough Tank water will discharge to ocean though a lock gate
when low tide, otherwise if required discharge to Primary tank through pipe & fittings. 9. The weighted Plunger fitted on the
Secondary Cylindrical Tank will act like a Hydraulic Machine and generates a huge Pressure Head at the Tank bottom as well as Inlet
pipe of Turbine. 10. High tide Ocean is a huge source of water and the Gravitational Energy is the cause of increasing Pressure Head
of water can run the Turbine fitted with Alternator and generates Huge Electrical Power.



Publication After 18 Months:

The following Patent Applications have been published under Section 11A (3) of The Patents (Amendment) Act, 2005. Any
Person may file representation by way of opposition to the Controller of Patents at the appropriate office against the grant of
the patent in the prescribed manner under section 25(1) of the Patents (Amendment) Act, 2005 read with the rule 55 of The
Patents (Amendment) Rules, 2006:
(19) INDIA

(54) Title of the invention : AN EMBEDDED SYSTEM FOR ANALYSIS OF MICROSTRIP-LIKE INTERCONNECTS

(51) International classification :G01R29/08; (71)Name of Applicant :
(31) Priority Document No :NA 1)JAYPEE UNIVERSITY OF INFORMATION
(32) Priority Date :NA TECHNOLOGY, WAKNAGHAT
(33) Name of priority country :NA Address of Applicant :P.O. DUMEHAR BANI,
(86) International Application No :NA KANDAGHAT, DISTT. SOLAN-173215 Himachal Pradesh
Filing Date :NA India
(87) International Publication No : NA (72)Name of Inventor :
(61) Patent of Addition to Application Number :NA 1)DR. ROHIT SHARMA
Filing Date :NA
Filing Date :NA
(57) Abstract :
Disclosed are computing device and methods for computing electrical characteristics of interconnect lines. The computing device
includes at least one processor and at least one memory comprising computer program code. The at least one memory and the
computer program code configured to, with the at least one processor, cause the computing device to receive interconnect input
associated with an interconnect line and calculate a Green's function corresponding to the geometrical dimensions. The interconnect
input includes geometrical dimensions of the interconnect line and at least one material constant. The Green's function is calculated
using transverse transmission line technique. Furthermore, the at least one memory and the computer program code configured to,
with the at least one processor, cause the computing device at least to compute one or more electrical characteristics of the
interconnect line based on at least one of the geometrical dimension, the Green's function and a variational analysis.



(19) INDIA

(54) Title of the invention : VOICE ASSISTED MANAGEMENT INFORMATION SYSTEM

(51) International classification :H04L (71)Name of Applicant :
(31) Priority Document No :NA 1)ABHYUDAY MISRA
(32) Priority Date :NA Address of Applicant :L-1/28, SECTOR-B, ALI GANJ,
(33) Name of priority country :NA LUCKNOW Uttar Pradesh India
Filing Date :NA 1)ABHYUDAY MISRA
(87) International Publication No :NA
Filing Date :NA
Filing Date :NA
(57) Abstract :
The invention uses voice and data based technologies in a manner which helps the users enter and retrieve data using simple devices
like cellular mobile phones, wired phones etc.



Patent office india published patent information - august 12th, 2011

Patent office india published patent information - august 12th, 2011

Empfohlen

Empfohlen

Weitere ähnliche Inhalte

Was ist angesagt?

Was ist angesagt? (17)

Ähnlich wie Patent office india published patent information - august 12th, 2011

Ähnlich wie Patent office india published patent information - august 12th, 2011 (17)

Mehr von InvnTree IP Services Pvt. Ltd.

Mehr von InvnTree IP Services Pvt. Ltd. (20)

Kürzlich hochgeladen

Kürzlich hochgeladen (20)

Patent office india published patent information - august 12th, 2011